These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 4742358)
21. Absorption of digoxin in patients with malabsorption syndromes. Heizer WD; Smith TW; Goldfinger SE N Engl J Med; 1971 Jul; 285(5):257-9. PubMed ID: 5090396 [No Abstract] [Full Text] [Related]
22. Effects of hypocholesterolemic interventions on digoxin bioavailability. Brown DD; Juhl RP; Warner SL Drug Metab Rev; 1979; 9(1):107-17. PubMed ID: 446263 [No Abstract] [Full Text] [Related]
23. [Resorption, degradation and excretion of acetyldigoxin in animal experiments]. Buchtela K; Drexler K; Hackl H; Königstein M; Schläger J Arzneimittelforschung; 1968 Mar; 18(3):295-303. PubMed ID: 5696004 [No Abstract] [Full Text] [Related]
24. Gastrointestinal dialysis of digoxin using cholestyramine. Rawashdeh NM; al-Hadidi HF; Irshaid YM; Battah AK Pharmacol Toxicol; 1993; 72(4-5):245-8. PubMed ID: 8372041 [TBL] [Abstract][Full Text] [Related]
25. The absorption of orally administered (12 - 3 H)digoxin in man. Beermann B; Hellström K; Rosén A Clin Sci; 1972 Oct; 43(4):507-18. PubMed ID: 4653590 [No Abstract] [Full Text] [Related]
26. Intestinal absorption of digoxin-3H in the rat. Caldwell JH; Martin JF; Dutta S; Greenberger NJ Am J Physiol; 1969 Dec; 217(6):1747-51. PubMed ID: 5353051 [No Abstract] [Full Text] [Related]
27. The excretion of tritiated digoxin in normal human volunteers before and after unilateral nephrectomy. Doherty JE; Flanigan WJ; Patterson RM; Dalrymple GV Circulation; 1969 Oct; 40(4):555-61. PubMed ID: 4898636 [No Abstract] [Full Text] [Related]
28. Pharmacodynamics of 3H-digoxin in infants. Hernandez A; Burton RM; Pagtakhan RD; Goldring D Pediatrics; 1969 Sep; 44(3):418-28. PubMed ID: 5809897 [No Abstract] [Full Text] [Related]
29. A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. Brown DD; Schmid J; Long RA; Hull JH J Clin Pharmacol; 1985; 25(5):360-4. PubMed ID: 4031112 [TBL] [Abstract][Full Text] [Related]
30. Decreased bioavailability of digoxin due to hypocholesterolemic interventions. Brown DD; Juhl RP; Warner SL Circulation; 1978 Jul; 58(1):164-72. PubMed ID: 647881 [No Abstract] [Full Text] [Related]
31. Dietary fiber or bile-sequestrant ingestion and divalent cation metabolism. Cassidy MM; Watkins DW Adv Exp Med Biol; 1989; 249():193-207. PubMed ID: 2543193 [No Abstract] [Full Text] [Related]
32. Interruption of the enterohepatic circulation of digitoxin by cholestyramine. II. Effect on metabolic disposition of tritium-labeled digitoxin and cardiac systolic intervals in man. Caldwell JH; Bush CA; Greenberger NJ J Clin Invest; 1971 Dec; 50(12):2638-44. PubMed ID: 5129315 [TBL] [Abstract][Full Text] [Related]
33. Persistence of hapten-antibody complexes in the circulation of immunized animals after a single intravenous injection of hapten. Schmidt DH; Kaufman BM; Butler VP J Exp Med; 1974 Feb; 139(2):278-94. PubMed ID: 4129823 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and metabolism of alpha-acetyldigoxin in man. Bodem G; Wirth K; Gernand E; Dengler HJ Arch Int Pharmacodyn Ther; 1974 Mar; 208(1):102-16. PubMed ID: 4846188 [No Abstract] [Full Text] [Related]
35. Drug-cholestyramine interactions. II. Influence of cholestyramine on GI absorption of sodium fusidate. Johns WH; Bates TR J Pharm Sci; 1972 May; 61(5):735-9. PubMed ID: 5035781 [No Abstract] [Full Text] [Related]
36. Pharmacokinetics of digoxin in the rat. Harrison LI; Gibaldi M Drug Metab Dispos; 1976; 4(1):88-93. PubMed ID: 3407 [TBL] [Abstract][Full Text] [Related]